Quarterly report pursuant to Section 13 or 15(d)

Summary of the Net Purchase Price and Allocation to the Acquired Assets (Detail)

v3.19.3
Summary of the Net Purchase Price and Allocation to the Acquired Assets (Detail) - ProstaGene, LLC - USD ($)
3 Months Ended
Aug. 31, 2019
May 31, 2019
Business Acquisition, Contingent Consideration [Line Items]    
CytoDyn Inc. Equity $ 11,558,000  
Acquisition Expenses 741,297  
Release of Deferred Tax Asset 2,826,919  
Total Cost of Acquisition 15,126,216  
Intangible assets 15,126,216 $ 15,126,216
Other 0  
Allocation of Acquisition Costs $ 15,126,216